Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Quinaux

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Breast Cancer|February 6, 2010
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancerAndré Robidoux, Aman U Buzdar, Emmanuel Quinaux, et al.
JAMA Oncology|December 7, 2018
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP GuidelinesMichael F Press, Jose A Seoane, Christina Curtis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98Sherene Loi, Nicolas Sirtaine, Fanny Piette, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAmir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
Breast Cancer Research : BCR|May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialLynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont, Marc Buyse, Jose Cortinas Abrahantes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast CancerParvin F Peddi, Peter A Fasching, Duan Liu, et al.
Breast Cancer Research and Treatment|September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trialEvandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsSara A Hurvitz, David J Betting, Howard M Stern, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Breast Cancer|February 6, 2010
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancerAndré Robidoux, Aman U Buzdar, Emmanuel Quinaux, et al.
JAMA Oncology|December 7, 2018
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP GuidelinesMichael F Press, Jose A Seoane, Christina Curtis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98Sherene Loi, Nicolas Sirtaine, Fanny Piette, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAmir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
Breast Cancer Research : BCR|May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialLynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont, Marc Buyse, Jose Cortinas Abrahantes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical TrialsMichael F Press, Guido Sauter, Marc Buyse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast CancerParvin F Peddi, Peter A Fasching, Duan Liu, et al.
Breast Cancer Research and Treatment|September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trialEvandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patientsSara A Hurvitz, David J Betting, Howard M Stern, et al.
Pageof 2